Mahmoud Alkhansa S, E Hassan Ammar M, Ali Amna A, Hassan Nuha M, Yousif Amna A, Elbashir Fawzia E, Omer Ahmed, Abdalla Omer M
Department of Radiobiology, Sudan Atomic Energy Commission, Khartoum, Sudan.
Department of Medical Physics, National Cancer Institute, University of Gezira, Wad Medani, Sudan.
Genome Integr. 2022 Mar 24;13:1. doi: 10.4103/genint.genint_1_22. eCollection 2022.
Radiotherapy is one of the most important options for treating breast cancer in humans. The development of biomarkers to monitor radiosensitivity is scarce. The aim of this study is to investigate the γH2AX levels in the human blood samples 0.5 h after radiotherapy compared to the levels before radiotherapy in breast cancer patients in relation to their respective body mass index (BMI). Blood plasma samples were collected from a total of 20 breast cancer patients before and after radiotherapy to measure γH2AX levels with an antibody against γH2AX based on enzyme-linked immunosorbent assay technique. The median BMI of the patients was 30 kg/m. γH2AX was differentially expressed in breast cancer patients before radiotherapy. γH2AX levels significantly increased in 14 patients after radiotherapy ( = 0.006), whereas γH2AX levels decreased in three patients after radiotherapy, and three patients were excluded. There was no correlation between γH2AX values after radiotherapy and BMI ( = 0.5, = 0.1). Our results suggest that γH2AX can be used by ELISA technique to measure γH2AX in the blood plasma of breast cancer patients undergoing radiotherapy and can be considered a biomarker of radiosensitivity.
放射治疗是治疗人类乳腺癌最重要的选择之一。用于监测放射敏感性的生物标志物的研究很少。本研究的目的是调查乳腺癌患者放疗后0.5小时人体血液样本中的γH2AX水平，并与放疗前的水平进行比较，同时考虑其各自的体重指数（BMI）。总共从20名乳腺癌患者放疗前后采集血浆样本，基于酶联免疫吸附测定技术，使用抗γH2AX抗体测量γH2AX水平。患者的中位BMI为30kg/m。γH2AX在放疗前的乳腺癌患者中差异表达。放疗后14名患者的γH2AX水平显著升高（P = 0.006），而放疗后3名患者的γH2AX水平下降，3名患者被排除。放疗后γH2AX值与BMI之间无相关性（P = 0.5，r = 0.1）。我们的结果表明，γH2AX可通过ELISA技术用于测量接受放疗的乳腺癌患者血浆中的γH2AX，并且可被视为放射敏感性的生物标志物。
